Evaxion (EVAX) has been informed that MSD (MRK) will not exercise its option for Evaxion’s Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner. Earlier this year MSD exercised its option on a separate Evaxion vaccine candidate, EVX-B3. Evaxion is eligible for milestone payments up to $592 million associated with the development of EVX-B3, as well as royalties on net sales.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million
- Evaxion Biotech: Innovative AI-Immunology Platform and Strategic Growth Potential Justify Buy Rating
- Evaxion Unveils Promising Data for AML Vaccine at ASH Meeting
- Evaxion Biotech presents new data for EVX-04
- Evaxion Biotech files to sell 38.45M ordinary shares for holders